Assessment of quality of life in musculo-skeletal health

C. Beaudart\*, E. Biver\*, O. Bruyère, C. Cooper, N. Al-Daghri, JY. Reginster, R. Rizzoli.

\* Co-first authors

Charlotte Beaudart (CB), PhD Student, Department of Public Health, Epidemiology and Health Economics, University of Liège, Quartier Hôpital, Avenue Hippocrate 13 – CHUB23, 4000 Liège, Belgium. E-mail : c.beaudart@ulg.ac.be

Emmanuel Biver (EB), MD PhD, Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle Perret-Gentil 4, CH-1211 Geneva 14, Switzerland. E-mail : Emmanuel.Biver@hcuge.ch

Olivier Bruyère (OB), PhD, Professor of Clinical Epidemiology and Professor of Geriatric Rehabilitation, Department of Public Health, Epidemiology and Health Economics, University of Liège, Quartier Hôpital, Avenue Hippocrate 13 – CHUB23, 4000 Liège, Belgium. E-mail : olivier.bruyere@ulg.ac.be

Cyrus Cooper (CC) ; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, England, UK; NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK; cc@mrc.soton.ac.uk

Nasser Al-Daghri (NAD); Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia; aldaghri2011@gmail.com

Jean-Yves Reginster (JYR), MD PhD, Director of the Bone, Cartilage and Muscle Metabolism Unit and Chair of the Department of Public Health Sciences, CHU Liège, Quai Godefroid Kurth 45, 4000 Liège, Belgium. E-mail : jyreginster@ulg.ac.be

René Rizzoli (RR), MD, Emeritus Professor of Medicine, Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle Perret-Gentil 4, CH-1211 Geneva 14, Switzerland. E-mail : Rene.Rizzoli@unige.ch

**Corresponding Author:**

Charlotte Beaudart

Email. c.beaudart@ulg.ac.be

Tel. 0032 43664933

Fax. 0032 43662812

Address. Avenue Hippocrate 13, CHU B23, 4000 Liège BELGIUM

**Abstract**

Musculoskeletal disorders affect morbidity, quality of life and mortality, and represent an increasing economic and societal burden in the context of population aging and increased life expectancy. Improvement of quality of life should be one of the priorities of any interventions to prevent and treat musculoskeletal disorders in the ageing population. Two main approaches, namely generic and disease-specific instruments, can be applied to measure health-related quality of life. Among the generic tools available in scientific literature, the short form 36 questionnaire (SF-36) and the Euroqol five item questionnaire (EQ-5D) are two of the most popular questionnaires used to quantify the health related quality of life in people with musculoskeletal disorders. However, because generic tools may not always be able to detect subtle effects of a specific condition on quality of life, a specific tool is highly valuable. Specific tools improve the ability to clinically characterize quality of life in subjects with a specific musculoskeletal disorder, as well as the capacity to assess changes over time in the QoL of these subjects. The recent development of specific tools should help to validate preventive and therapeutic interventions in this field.

**Introduction**

With population aging and increased life expectancy, people are now living longer and are becoming increasingly susceptible to non-communicable diseases, in particular musculoskeletal disorders1. Musculoskeletal diseases increase with age and represent the 4th leading contributors to disease burden in older people after cardiovascular diseases, malignant neoplasms and chronic respiratory diseases2. Their burden also increases with age and will further increase with ageing of the global population3. The burden attributable to musculoskeletal disorders is estimated having increased by 46% from 1990 to 20104. The increase of socio-demographic status also contributes to higher disability-adjusted life-years (DALYs) associated with musculoskeletal diseases5.

Musculoskeletal aging is a very large phenotype including four main conditions, osteoporosis, osteoarthritis, sarcopenia and frailty, which are associated with adverse outcomes such as falls, fractures, functional decline or increased mortality6–10. All of them highly affect disability and independence levels, quality of life and demands on health systems11–13. For instance, at the age of 50, the lifetime risk of any osteoporotic fracture lies within 50% in women and 20% in men, and further increases with advancing age14,15. Osteoporosis is a major risk of fractures, but sarcopenia itself also increases the risk of fracture16,17, possibly via an increase of the risk of falls18. A vicious circle of musculoskeletal aging arises, leading to chronic pain, loss of mobility and slowness with their multiple clinical and societal consequences19.

**Burden of musculo-skeletal disorders**

Patients with musculoskeletal disorders experience loss of mobility, of independence, higher rates of institutionalisation and higher mortality rates. As a consequence, all musculoskeletal disorders significantly impairs patients’ health-related quality of life20–23, and generate at the societal level high direct and indirect healthcare costs. Among injuries resulting from low trauma falls, hip and vertebral fractures lead to the greatest activities of daily living limitations immediately after the fall24. Only 40 to 70% of hip fracture survivors recover their pre-fracture level of mobility, ability and independence to perform activities of daily living, and a substantial proportion requires assistance for various tasks in the 2 years after fracture, although they were independent before fracture25. Fractures also generate high hospital and healthcare costs which can remain above pre-fracture levels 5 years following the index fracture26,27. In Switzerland during 2000, the overall incidences of hospitalization due to fractures were 969 and 768 per 100,000 in women and men, respectively, showing that osteoporosis continued to be a heavy burden on the healthcare systems28,29. There is a high risk of transfer to a long-term care facility following osteoporotic fractures, reaching 10 to 30% of patients in the year following hospital discharge after hip fracture25,30. This risk is about 3 times greater after hospitalization for a hip fracture or other fall-related injuries than for a non–fall-related reason31.

Sarcopenia also significantly impacts self-reported quality of life and physical activity level32,33. In women from the prospective Study of Osteoporotic Fractures, it has been shown that slowness was associated with greater health care utilization, including greater number of hospitalizations, rate of hospitalization days and likelihood of a short-term skilled nursing facility stay than women without slowness34. Musculoskeletal disorders and their consequences are also associated with increased mortality risk. This has been shown for after low-trauma fractures35–37, in patients with painful osteoarthritis38 or with sarcopenia or deficits in mobility, even after adjustment for confounding factors39,40. This burden is deemed to increase, driven by population aging, and largely exceeds service capacity, leading to a substantial treatment gap, in particular in the context of osteoporosis in which fractures are however preventable29,41.

**Assessment of quality of life in musculoskeletal disorders**

Health-Related Quality of Life (HRQoL) is considered to be a subjective assessment of the impact of disease and treatment across physical, psychological, social and somatic domains of functioning and well-being42. This is also one of the most important concept in all medical illnesses that involves all relevant factors to health status directly and indirectly. HRQoL is also an important measure of a patient's perception of his/her illness. Measurement of HRQoL has become increasingly important in research and clinic over the past three decades. Randomised controlled trials as well as observational studies increasingly include QoL measures, usually as a secondary endpoint. Moreover, many medical interventions are now designed to improve quality of life rather than prolong the life. Additionally, there are studies utilizing measures of QoL as predictors, for example of physical decline or death43,44. Inclusion of QoL measures into studies is no longer restricted to highly developed western countries, but now includes countries from all over the world45,46.

Research published clinical practice guidelines recommending providers to routinely evaluate patients’ HRQoL and use their assessment to modify and guide patient care47. Two main approaches, namely generic and disease-specific instruments, can be applied to measure HRQoL48.

* 1. Generic tools to assess quality of life in musculoskeletal health

Generic HR-QOL instruments are designed to be applicable across a wide range of populations and interventions. Indeed, these simple and effective instruments49 are designed to focus on domains of quality of life that can be expected to be affected by health-care interventions. They are therefore widely used in observational studies and clinical studies since they allow comparison between, for example, different populations suffering from a same disease or comparison of the quality of life impact of the disease based on the state of the disease.

Among the generic tools available in scientific literature, the short form 36 questionnaire (SF-36) and the Euroqol five item questionnaire (EQ-5D) are two of the most popular questionnaires used to quantify the health related quality of life in people with musculoskeletal disorders. The SF-36 questionnaire50 is composed of 36 items measuring 8 health-related quality of health domains (physical functioning, role limitation due to physical problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problem, and mental health). The EQ-5D questionnaire is also a generic tool51, which records the level of self-reported problems according to five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).

Studies employing the SF-36 have been undertaken in patients presenting various musculoskeletal disorders such as chronic back disorders52–54, arthritis55–57, osteoarthritis58, rheumatoid arthritis59, spinal problems60,61, fibromyalgia62,63 but also sarcopenia64–66. The EQ-5D has also been used for disorders such as back disorders67,68, osteoarthritis of the knee69, rheumatoid arthritis70,71, sarcopenia64,72 and several musculoskeletal diseases73.

A study including 3664 participants assessed the prevalence of twelve common musculoskeletal disorders74. Results reported that subjects with musculoskeletal diseases (n=1776) had a worst quality of life compared to those without any musculoskeletal conditions (n=1888). Lower scores were found for all SF-36 dimensions. The worsted results were found for fibromyalgia, osteoporosis of the hip, osteoporosis and rheumatoid arthritis, one again across all domains of the SF-36 questionnaire. Subjects with a musculoskeletal disease were also reported more health problems on the EQ-5D dimensions than those without a musculoskeletal disease. Subjects suffering from a musculoskeletal diseases presented therefore more problems on mobility (29.9% versus 10.5%), self-care (6.6% versus 2.3%), usual activities (34.5% versus 12.4%), pain/discomfort (62.5% versus 31.2%) and, finally, anxiety/depression (23.3% versus 14.8%).

One of the major criticisms highlighted against the use of generic quality of life questionnaire is that these instruments, designed to measure HRQoL over a broad spectrum of diseases, may not be sensitive enough to detect HRQoL specific to a particular illness of interest. Indeed, they are often based on a relatively narrow focus on the concept of health and therefore, they address only a selective number of domains. Moreover, they carry the risk of being insensitive to changes over time or treatment. In some specific musculoskeletal condition, such as sarcopenia for example, it is acknowledged that generic tools should be supplemented with disease-specific instruments75.

* 1. Specific tools to assess quality of life in musculoskeletal health

Because generic tools may not always be able to detect subtle effects of a specific condition on QoL, a specific tool is highly valuable to assess the impact of musculoskeletal conditions on QoL. A large number of disease specific tools already exist in the field of musculoskeletal health. In the field of osteoporosis, for example, no less than 6 specific health-related quality of life tools are available (Qualeffo-4148,76, questionnaire QoL in Osteoporosis [QUALIOST]77, osteoporosis assessment questionnaire [OPAQ]78, osteoporosis QoL questionnaire [OQLQ]79, osteoporosis functional disability questionnaire [OFDQ]80 and osteoporosis-targeted QoL questionnaire [OPTQoL]81). Specific quality of life questionnaires are also available for other conditions, such as arthritis in general (e.g. WOMAC, rheumatoid arthritis quality of life [RAQoL]82) but also for some specific form of arthritis such as knee and hip arthrisits (osteoarthritis knee and hip quality of life questionnaire [OAKHQOL]83) or psoriatic arthritis (PsAQoL questionnaire84). Other specific quality of life questionnaires have also been found for sarcopenia (sarcopenia & quality of life questionnaire [SarQoL]85) and fibromyalgia (fibromyalgia impact questionnaire and its revised version [FIQ]86).

Specific tools improve the ability to clinically characterize QoL in subjects with a specific musculoskeletal disorder, as well as the capacity to assess changes over time in the QoL of these subjects. Even if therapeutic interventions in the field of sarcopenia and frailty are still in their infancy87,88, these tools can be used to assess the relevance of interventions and their effectiveness in terms of change in quality of life. The disadvantage of specific tools is that they do not offer the possibility to compare quality of life of subjects with other types of population.

**Conclusion:**

Musculoskeletal disorders are major health conditions associated with ageing, which affect morbidity, quality of life and mortality, and contribute to increase healthcare costs for the society. In the context of population ageing, of improvement of life expectancy and of the consensual previsions of marked increase of the proportion of older people, they represent a great challenge to limit their current and future economic and societal burden. Improvement of quality of life should be the priority of any interventions to prevent and treat osteoporosis, osteoarthritis and sarcopenia in the ageing population. The recent development of tools dedicated to the assessment of QOL related to musculoskeletal conditions should help to validate such interventions.

**Acknowledgements**

We thank the Prince Mutaib Bin Abdullah Chair for Biomarkers of Osteoporosis and Deanship of Scientific Research, King Saud University for their support

**Conflict of interest**

Charlotte Beaudart, Olivier Bruyère and Jean-Yves Reginster are the shareholder of SarQoL® sprl. Others authors have no relevant competing interests to declare.

**References**

1. Hoy, D. G. *et al.* The global burden of musculoskeletal conditions for 2010: an overview of methods. *Ann. Rheum. Dis.* **73,** 982–9 (2014).

2. Prince, M. J. *et al.* The burden of disease in older people and implications for health policy and practice. *Lancet (London, England)* **385,** 549–62 (2015).

3. Chatterji, S. *et al.* Health, functioning, and disability in older adults--present status and future implications. *Lancet (London, England)* **385,** 563–75 (2015).

4. March, L. *et al.* Burden of disability due to musculoskeletal (MSK) disorders. *Best Pract. Res. Clin. Rheumatol.* **28,** 353–66 (2014).

5. Murray, C. J. L. *et al.* Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. *Lancet* **386,** 2145–2191 (2015).

6. Beaudart, C. *et al.* Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. *PLoS One* **12,** e0169548 (2017).

7. Cesari, M. *et al.* Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial. *Aging Clin. Exp. Res.* **29,** 81–88 (2017).

8. Marzetti, E. *et al.* Sarcopenia: an overview. *Aging Clin. Exp. Res.* **29,** 11–17 (2017).

9. Cruz-Jentoft, A. J., Kiesswetter, E., Drey, M. & Sieber, C. C. Nutrition, frailty, and sarcopenia. *Aging Clin. Exp. Res.* **29,** 43–48 (2017).

10. Bartley, M. M. *et al.* Frailty and Mortality Outcomes in Cognitively Normal Older People: Sex Differences in a Population-Based Study. *J. Am. Geriatr. Soc.* **64,** 132–137 (2016).

11. Dawson, A. & Dennison, E. Measuring the musculoskeletal aging phenotype. *Maturitas* **93,** 13–17 (2016).

12. Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. *Lancet (London, England)* **359,** 1761–7 (2002).

13. Cross, M. *et al.* The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann. Rheum. Dis.* **73,** 1323–30 (2014).

14. Johnell, O. & Kanis, J. Epidemiology of osteoporotic fractures. *Osteoporos. Int.* **16 Suppl 2,** S3-7 (2005).

15. Lippuner, K., Johansson, H., Kanis, J. A. & Rizzoli, R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. *Osteoporos. Int.* **20,** 1131–40 (2009).

16. Hars, M. *et al.* Low Lean Mass Predicts Incident Fractures Independently From FRAX: a Prospective Cohort Study of Recent Retirees. *J. Bone Miner. Res.* (2016). doi:10.1002/jbmr.2878

17. Scott, D. *et al.* Associations of Sarcopenic Obesity and Dynapenic Obesity with Bone Mineral Density and Incident Fractures Over 5-10 Years in Community-Dwelling Older Adults. *Calcif. Tissue Int.* **99,** 30–42 (2016).

18. Bischoff-Ferrari, H. A. *et al.* Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. *Osteoporos. Int.* **26,** 2793–802 (2015).

19. Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y. & Biver, E. Sarcopenia: burden and challenges for public health. *Archives of Public Health* **72,** 45 (2014).

20. Xie, F. *et al.* Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. *Pharmacoeconomics* (2016). doi:10.1007/s40273-016-0424-x

21. Abimanyi-Ochom, J. *et al.* Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). *Osteoporos. Int.* **26,** 1781–90 (2015).

22. Tarride, J.-E. *et al.* Loss of health related quality of life following low-trauma fractures in the elderly. *BMC Geriatr.* **16,** 84 (2016).

23. Al-Sari, U. A., Tobias, J. & Clark, E. Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. *Osteoporos. Int.* **27,** 2891–900 (2016).

24. Yu, W.-Y., Hwang, H.-F., Hu, M.-H., Chen, C.-Y. & Lin, M.-R. Effects of fall injury type and discharge placement on mortality, hospitalization, falls, and ADL changes among older people in Taiwan. *Accid. Anal. Prev.* **50,** 887–94 (2013).

25. Dyer, S. M. *et al.* A critical review of the long-term disability outcomes following hip fracture. *BMC Geriatr.* **16,** 158 (2016).

26. Leslie, W. D. *et al.* Direct healthcare costs for 5 years post-fracture in Canada: a long-term population-based assessment. *Osteoporos. Int.* **24,** 1697–705 (2013).

27. Leal, J. *et al.* Impact of hip fracture on hospital care costs: a population-based study. *Osteoporos. Int.* **27,** 549–58 (2016).

28. Lippuner, K., Golder, M. & Greiner, R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. *Osteoporos. Int.* **16 Suppl 2,** S8–S17 (2005).

29. Svedbom, A., Ivergård, M., Hernlund, E., Rizzoli, R. & Kanis, J. A. Epidemiology and economic burden of osteoporosis in Switzerland. *Arch. Osteoporos.* **9,** 187 (2014).

30. Morin, S. *et al.* Institutionalization following incident non-traumatic fractures in community-dwelling men and women. *Osteoporos. Int.* **23,** 2381–6 (2012).

31. Gill, T. M., Murphy, T. E., Gahbauer, E. A. & Allore, H. G. Association of injurious falls with disability outcomes and nursing home admissions in community-living older persons. *Am. J. Epidemiol.* **178,** 418–25 (2013).

32. Verlaan, S. *et al.* Nutritional status, body composition, and quality of life in community-dwelling sarcopenic and non-sarcopenic older adults: A case-control study. *Clin. Nutr.* (2015). doi:10.1016/j.clnu.2015.11.013

33. Filippin, L. I., Teixeira, V. N. de O., da Silva, M. P. M., Miraglia, F. & da Silva, F. S. Sarcopenia: a predictor of mortality and the need for early diagnosis and intervention. *Aging Clin. Exp. Res.* **27,** 249–54 (2015).

34. Cawthon, P. M. *et al.* Sarcopenia and Health Care Utilization in Older Women. *J. Gerontol. A. Biol. Sci. Med. Sci.* glw118 (2016). doi:10.1093/gerona/glw118

35. Morin, S. *et al.* Mortality rates after incident non-traumatic fractures in older men and women. *Osteoporos. Int.* **22,** 2439–48 (2011).

36. Bliuc, D. *et al.* Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA* **301,** 513–21 (2009).

37. von Friesendorff, M. *et al.* Hip fracture, mortality risk, and cause of death over two decades. *Osteoporos. Int.* **27,** 2945–53 (2016).

38. Kluzek, S. *et al.* Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women. *Ann. Rheum. Dis.* **75,** 1749–56 (2016).

39. De Buyser, S. L. *et al.* Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. *Age Ageing* **45,** 602–8 (2016).

40. Ensrud, K. E. *et al.* Effects of Mobility and Cognition on Risk of Mortality in Women in Late Life: A Prospective Study. *J. Gerontol. A. Biol. Sci. Med. Sci.* **71,** 759–65 (2016).

41. Briggs, A. M. *et al.* Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. doi:10.1093/geront/gnw002

42. Revicki, D. A. *et al.* Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. *Qual. Life Res.* **9,** 887–900 (2000).

43. Ul-Haq, Z. *et al.* Association between physical and mental health-related quality of life and adverse outcomes; a retrospective cohort study of 5,272 Scottish adults. *BMC Public Health* **14,** 1197 (2014).

44. Trombetti, A. *et al.* Age-associated declines in muscle mass, strength, power, and physical performance: impact on fear of falling and quality of life. *Osteoporos. Int.* **27,** 463–71 (2016).

45. Nglazi, M. D. *et al.* Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa. *BMC Public Health* **14,** 676 (2014).

46. Zhou, J. *et al.* Individual and household-level predictors of health related quality of life among middle-aged people in rural Mid-east China: a cross-sectional study. *BMC Public Health* **14,** 660 (2014).

47. Guyatt, G. H., Bombardier, C. & Tugwell, P. X. Measuring disease-specific quality of life in clinical trials. *CMAJ* **134,** 889–895 (1986).

48. Rizzoli, R. *et al.* Quality of life in sarcopenia and frailty. *Calcif Tissue Int* **93,** 101–120 (2013).

49. Syddall, H. E., Martin, H. J., Harwood, R. H., Cooper, C. & Aihie Sayer, A. The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. *J Nutr Heal. Aging* **13,** 57–62 (2009).

50. Ware Jr., J. E. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* **30,** 473–483 (1992).

51. Rabin, R. & de Charro, F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med* **33,** 337–343 (2001).

52. Ahrens, C., Schiltenwolf, M. & Wang, H. [Health-related quality of life (SF-36) in chronic low back pain and comorbid depression]. *Schmerz* **24,** 251–6 (2010).

53. Adorno, M. L. G. R. & Brasil-Neto, J. P. Assessment of the quality of life through the SF-36 questionnaire in patients with chronic nonspecific low back pain. *Acta Ortop. Bras.* **21,** 202–7 (2013).

54. Veresciagina, K., Ambrozaitis, K. V. & Spakauskas, B. Health-related quality-of-life assessment in patients with low back pain using SF-36 questionnaire. *Medicina (Kaunas).* **43,** 607–13 (2007).

55. Talamo, J., Frater, A., Gallivan, S. & Young, A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. *Rheumatology* **36,** 463–469 (1997).

56. Kosinski, M., Keller, S. D., Ware, J. E., Hatoum, H. T. & Kong, S. X. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. *Med. Care* **37,** MS23-39 (1999).

57. Hill, C. L., Parsons, J., Taylor, A. & Leach, G. Health related quality of life in a population sample with arthritis. *J. Rheumatol.* **26,** 2029–35 (1999).

58. Angst, F., Aeschlimann, A., Steiner, W. & Stucki, G. Responsiveness of the WOMAC osteoarthritis index as compared with the SF-36 in patients with osteoarthritis of the legs undergoing a comprehensive rehabilitation intervention. *Ann. Rheum. Dis.* **60,** 834–40 (2001).

59. Matcham, F. *et al.* The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. *Semin. Arthritis Rheum.* **44,** 123–130 (2014).

60. Zanoli, G., Jönsson, B. & Strömqvist, B. SF-36 scores in degenerative lumbar spine disorders: analysis of prospective data from 451 patients. *Acta Orthop.* **77,** 298–306 (2006).

61. Guilfoyle, M. R., Seeley, H. & Laing, R. J. The Short Form 36 health survey in spine disease--validation against condition-specific measures. *Br. J. Neurosurg.* **23,** 401–5 (2009).

62. Neumann, L., Berzak, A. & Buskila, D. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). *Semin. Arthritis Rheum.* **29,** 400–8 (2000).

63. Salaffi, F. *et al.* Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. *Clin. Exp. Rheumatol.* **27,** S67-74

64. Beaudart, C. *et al.* Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. *Exp. Gerontol.* (2015). doi:10.1016/j.exger.2015.05.003

65. Yadav, A. *et al.* Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. *Clin. Transplant.* **29,** 134–41 (2015).

66. Silva Neto, L. S., Karnikowiski, M. G., Tavares, A. B. & Lima, R. M. Association between sarcopenia, sarcopenic obesity, muscle strength and quality of life variables in elderly women. *Rev Bras Fisioter* **16,** 360–367 (2012).

67. Johnsen, L. G. *et al.* Comparison of the SF6D, the EQ5D, and the oswestry disability index in patients with chronic low back pain and degenerative disc disease. *BMC Musculoskelet. Disord.* **14,** 148 (2013).

68. Whynes, D. K. *et al.* Responsiveness of the EQ-5D health-related quality-of-life instrument in assessing low back pain. *Value Health* **16,** 124–32

69. Fransen, M. & Edmonds, J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. *Rheumatology* **38,** 807–813 (1999).

70. Hernandez Alava, M., Wailoo, A., Wolfe, F. & Michaud, K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. *Rheumatology* **52,** 944–950 (2013).

71. Hurst, N. P., Kind, P., Ruta, D., Hunter, M. & Stubbings, A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Rheumatology* **36,** 551–559 (1997).

72. Go, S. W., Cha, Y. H., Lee, J. A. & Park, H. S. Association between Sarcopenia, Bone Density, and Health-Related Quality of Life in Korean Men. *Korean J. Fam. Med.* **34,** 281–8 (2013).

73. Wolfe, F. & Hawley, D. J. Measurement of the quality of life in rheumatic disorders using the EuroQol. *Br. J. Rheumatol.* **36,** 786–93 (1997).

74. Picavet, H. S. J. & Hoeymans, N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. *Ann. Rheum. Dis.* **63,** 723–9 (2004).

75. Ware JE Jr (1996) The SF-36 Health Survey. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadalphia, pp 337–344.

76. Lips, P. *et al.* Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. *Osteoporos. Int.* **10,** 150–60 (1999).

77. Marquis, P., Cialdella, P. & De la Loge, C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. *Qual. Life Res.* **10,** 555–66 (2001).

78. Randell, A. G. *et al.* Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. *J. Rheumatol.* **25,** 1171–9 (1998).

79. Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group. *Osteoporos. Int.* **7,** 478–87 (1997).

80. Helmes, E. *et al.* A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. *J. Gerontol. A. Biol. Sci. Med. Sci.* **50,** M91-8 (1995).

81. Lydick, E. *et al.* Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). *J. Bone Miner. Res.* **12,** 456–63 (1997).

82. Tijhuis, G. J. *et al.* The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. *Rheumatology* **40,** 1112–1119 (2001).

83. Rat, A.-C. *et al.* OAKHQOL: a new instrument to measure quality of life in knee and hip osteoarthritis. *J. Clin. Epidemiol.* **58,** 47–55 (2005).

84. McKenna, S. P. *et al.* Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. *Ann. Rheum. Dis.* **63,** 162–9 (2004).

85. Beaudart, C. *et al.* Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. *Age Ageing* **44,** 960–966 (2015).

86. Bennett, R. M. *et al.* The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. *Arthritis Res. Ther.* **11,** R120 (2009).

87. Reginster, J.-Y. *et al.* Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. *Aging Clin. Exp. Res.* **28,** 47–58 (2016).

88. Landi, F. *et al.* The ?Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies? (SPRINTT) randomized controlled trial: design and methods. *Aging Clin. Exp. Res.* **29,** 89–100 (2017).